OBJECTIVES: In France, 10% of people with diabetes have type 1 diabetes (T1D), which is associated with a heavy clinical, humanistic and economic burden, and requires lifelong insulin treatment and can lead to major complications 10 to 20 years after disease onset. The main objective of the HEROES-1 study is to estimate incidence and prevalence of T1D in France from 2018-2022. Secondary objectives include a description of patients’ characteristics, T1D-related complications, healthcare resource use and disease management costs in total and by subgroups of interest, i.e. age, age at disease onset and diabetes duration.

METHODS: An observational retrospective study was conducted using the French ESND (Echantillon du Système National des Données de Santé, which include 2% of the SNDS – Système National des Données de Santé). Among insulin-treated patients with diabetes, incident patients were identified based on age at first hospitalization (≤35 years) and duration between first hospitalization or LTD for diabetes and first insulin dispensation (≤ 12 months). Patients with other types of diabetes (treated with non-insulin antidiabetics, iatrogenic diabetes, diabetes secondary to pancreatic disease or neonatal diabetes) were excluded. Secondly, prevalent non-incident patients were identified based on LTD or hospitalization with T1D diagnosis and the same exclusion criteria (other type of diabetes) as for incidents were applied. With 5 years of follow-back and follow-up until end of 2022, clinical outcomes, patients’ characteristics, healthcare consumption and related costs were collected from the database.

RESULTS: First results on the ESND extrapolated to the French population, concluded in 20,500 incident (≤35 years) over 5 years (approximately 4,000 per year) and estimated 179,850 prevalent T1D patients between 2018 and 2022 with 54.9% of men and a mean age of 43.4 years.

CONCLUSIONS: The number of patients with type 1 diabetes in France is consistent with literature. Next analyses will include T1D-related complications and healthcare resource use.